Thats why were striving for the personal side of healthcare
Say your vial says Tirzepatide 10 mg / 1 mL
This product is FDA-approved and manufactured to meet United States Pharmacopeia (USP) monograph standards and current Good Manufacturing Practice (cGMP) requirements
Injection burden 12 injections most days Best for Independent dose control Cycle driver Compound-specific phasing BPC-157 Loading 250500 mcg, daily Frequency Daily Maintenance 250 mcg, daily Route SubQ TB-500 Loading 2.05.0 mg, 2x/week Frequency 2x/week (loading), 12x/week (maintenance) Maintenance 2.0 mg, 12x/week Route SubQ Example Weekly Schedule (Loading Phase) Monday BPC-157 500 mcg SubQ + TB-500 2.5 mg SubQ Tuesday BPC-157 500 mcg SubQ Wednesday BPC-157 500 mcg SubQ Thursday BPC-157 500 mcg SubQ + TB-500 2.5 mg SubQ Friday BPC-157 500 mcg SubQ Saturday BPC-157 500 mcg SubQ Sunday BPC-157 500 mcg SubQ Use separate sterile syringes for separate-vial draws
Alcohol wipes should be used before and after any puncture with a needle
For example, by using changes in body temperature to trigger the release of drugs, personalized disease treatment can be achieved